Chemotherapy Dose Adjustment in Obese Patient
Article Sidebar
Main Article Content
Abstract
Background: Obesity is associated with increasing risk of cancers. However chemotherapy dosing in obese patient has been reported under recommended dose according to toxicity concern. This study therefore reported the chemotherapy dose adjustment and safety outcome in obese cancer patient.
Objective: To describe chemotherapy dose adjustment pattern and safety outcome in obese cancer patient at Surin hospital
Study Design: cross-sectional study
Methods: A retrospective review of obese patient receiving chemotherapy at Surin hospital was conducted during January 1 to 31 December 2014. Patient’s characteristic, ideal body weight, body surface area and adverse reaction during chemotherapy courses were collected for data analysis. Research data was analyzed and presented with percentage, mean with standard deviation. Comparative tests were paired t-test, chi-square and fisher’s exact test.
Results: There were 43 obese patients (7.9%) from overall 541 cancer patients receiving chemotherapy during period of this study. Obese patients were mostly female (40 cases) with average age 53.5 ± 8.2 years and average body mass index was 28.5 ± 4.3 kg/m. Breast cancer was the most prevalent among obese cancer patients (58.14%). Thirty-nine obese cancer patients received chemotherapy based on body surface area of their ideal body weight while only 4 patients received full-based weight chemotherapy dose. Relative chemotherapy dose intensity in obese patient was 0.9 ±0.1 (p = 0.002). Serious adverse drug reactions of anemia and mucositis had been reported.
Conclusion: Despite most of obese cancer patients were assigned adjusted chemotherapy dose based on their ideal body weight, the relative dose intensity was not significantly different. Few serious adverse events were observed and further efficacy outcome had been suggested.
Article Details
References
2. Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc 2008:67:2:128-45.
3. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M. et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 2015;16:l:36-46.
4. Lashinger LM, Rossi EL, Hursting SD. Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation. Clin Pharmacol Ther 2014;96:4:458-63.
5. Bowers LW, Rossi EL, O'Flanagan CH, deGraffenried LA, Hursting SD. The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol 2015;6:77.
6. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 2013;24:6:503-13.
7. Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol 2015;138:1:201-6.
8. Chambers P, Daniels SH, Thompson LC, Stephens RJ. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 2012;23:3:748-53.
9. Hourdequin KC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal- weight patients: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO 2013;24:12:2952-62.
10. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM. et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:13:1553-61.
11. Minghelli B, Nunes C, Oliveira R. Body mass index and waist circumference to define thinness, overweight and obesity in Portuguese adolescents: comparison between CDC, IOTF, WHO references. Pediatr Endocrinol Rev PER 2014;12:1:35-41.
12. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC. et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014;106:9.
13. Hansen J, stephan J-M, Freesmeier M, Bender D, Button A, Goodheart MJ. The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients. Gynecol Oncol 2015:138:1:154-8.
14. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC. et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol Off J Am Soc Clin Oncol 1996:14:11:3000-8.
15. Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressel M, Mileshkin L. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 2014:133:1:16-22.
